FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, to experimental gastroenterology. 5 ml of an ozone-oxygen mixture with a 1.0 to 1.2 mg/l concentration of ozone is injected intraperitoneally in 2 to 6 procedures 1 time a day. The presence of a therapeutic effect is deduced if ulcers of the intestinal wall are recorded as healed during histological studies of the preparation of the large intestine and if a statistically significant decrease in the concentration of IL-17 in blood serum is found compared with animals of the comparison group on the 6th day of the experiment.
EFFECT: possibility of effectively treating ulcerative colitis in an experiment; reparative and anti-inflammatory effect.
1 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR RECTAL APPLICATION OF OZONE IN A MODEL OF ULCERATIVE COLITIS | 2022 |
|
RU2787973C1 |
| METHOD OF TREATING PATIENTS WITH ULCERATIVE COLITIS | 2009 |
|
RU2419443C1 |
| METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2807131C1 |
| METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2814765C1 |
| METHOD FOR TREATING ULCERATIVE COLITIS | 2000 |
|
RU2165758C1 |
| METHOD FOR TREATING INFLAMMATORY DISEASES OF TERMINAL COLON | 2022 |
|
RU2807235C1 |
| METHOD FOR INDIVIDUAL SENSITIVITY TO PREPARATIONS OF 5-AMINOSALYCILIC ACID (5-ASA) IN PATIENTS WITH ULCEROUS COLITIS | 2005 |
|
RU2287819C1 |
| DOSAGE FORM FOR TREATING AND PREVENTING ULCERATIVE COLITIS, CONTAINING PEGYLATED LIPOSOMAL FORM OF ERYTHROPOIETIN IN FORM OF SUPPOSITORIES, HAVING ANTI-INFLAMMATORY AND IMMUNOMODULATORY EFFECT | 2020 |
|
RU2740060C1 |
| MELATONIN AGENT FOR TREATING INFLAMMATORY BOWEL DISEASES IN THE FORM OF RECTAL SUPPOSITORIES | 2023 |
|
RU2819721C1 |
| METHOD OF TREATING COMPLICATIONS IN PATIENTS WITH CHRONIC NONSPECIFIC ULCERATIVE COLITIS | 2015 |
|
RU2607160C2 |
